BioCentury
ARTICLE | Clinical News

ProCervix: Additional Phase II data

July 18, 2016 7:00 AM UTC

Additional data from 233 evaluable patients ages 25-50 infected with HPV types 16 and/or 18 in the double-blind, European Phase II RHEIA-VAC trial showed that 2 intradermal vaccinations of 600 ug GTL0...